ReviewJugan geon-gang gwa jilbyeong2025
[Overview of PCR-based Diagnostic Assays for Emerging Infectious Disease Pathogens].
Review in Jugan geon-gang gwa jilbyeong, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Neonatal Intensive Care Unit Outbreak ofPathogens (Basel, Switzerland) · 2026Article
- Activity-Based Costing of COVID-19 RT-PCR Testing in Public Laboratories in Indonesia: Evidence for Tariff Setting.ClinicoEconomics and outcomes research : CEOR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Continuous genetic variation in pathogens enhances their infectious potential and promotes the emergence of infectious disease outbreaks, highlighting the need for diagnostic technologies capable of broad-range detection. Herein, we introduce pan-polymerase chain reaction (pan-PCR) and multiplex PCR assays to identify the causative agents of emerging or unknown infectious diseases. Methods: To introduce the research, development, and practical applications of pan-PCR and multiplex PCR assays for pathogen diagnosis, a comprehensive review was conducted. The review focused on recent domestic and international institutional reports and academic literature on public health and PCR-based diagnostic methods. Literature published since the coronavirus disease 2019 pandemic was included. Results: Both technologies have been recognized as core diagnostic approaches to effectively respond to emerging and unknown infectious diseases. Pan-PCR uses conserved gene regions for the initial screening of unknown pathogens, whereas multiplex PCR is used to simultaneously identify specific pathogens, including co-infection cases. These two technologies could be utilized complementarily to identify the causative agents of emerging infectious diseases. Conclusions: Pan-PCR and multiplex PCR show promise as key diagnostic platforms to facilitate proactive responses in the face of infectious disease threats in the future. The simultaneous use of both technologies, capitalizing on their respective strengths in versatility and specificity, is likely to improve diagnostic capabilities for emerging or unknown infectious diseases and strengthen public health surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.